| Literature DB >> 29444977 |
Giovanna Cutrona1, Claudio Tripodo2, Serena Matis3, Anna Grazia Recchia4,5, Carlotta Massucco3, Marina Fabbi6, Monica Colombo3, Laura Emionite7, Sabina Sangaletti8, Alessandro Gulino2, Daniele Reverberi3, Rosanna Massara3, Simona Boccardo9, Daniela de Totero3, Sandra Salvi9, Michele Cilli7, Mariavaleria Pellicanò4,5, Martina Manzoni10,11, Sonia Fabris11, Irma Airoldi12, Francesca Valdora3,13, Silvano Ferrini6, Massimo Gentile4,5, Ernesto Vigna4,5, Sabrina Bossio5, Laura De Stefano5, Angela Palummo5, Giovanni Iaquinta5, Martina Cardillo13, Simonetta Zupo14, Giannamaria Cerruti14, Adalberto Ibatici15, Antonino Neri10,11, Franco Fais3,13, Manlio Ferrarini16, Fortunato Morabito4,5.
Abstract
Although the progression of chronic lymphocytic leukemia (CLL) requires the cooperation of the microenvironment, the exact cellular and molecular mechanisms involved are still unclear. We investigated the interleukin (IL)-23 receptor (IL-23R)/IL-23 axis and found that circulating cells from early-stage CLL patients with shorter time-to-treatment, but not of those with a more benign course, expressed a defective form of the IL-23R complex lacking the IL-12Rβ1 chain. However, cells from both patient groups expressed the complete IL-23R complex in tissue infiltrates and could be induced to express the IL-12Rβ1 chain when cocultured with activated T cells or CD40L+ cells. CLL cells activated in vitro in this context produced IL-23, a finding that, together with the presence of IL-23 in CLL lymphoid tissues, suggests the existence of an autocrine/paracrine loop inducing CLL cell proliferation. Interference with the IL-23R/IL-23 axis using an anti-IL-23p19 antibody proved effective in controlling disease onset and expansion in xenografted mice, suggesting potential therapeutic strategies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29444977 DOI: 10.1126/scitranslmed.aal1571
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956